You are here

Pharmaceutical-Approval Update: Oncology April 2005

Marvin M. Goldenberg, PhD, RPh, MS
PDF version: 
The author discusses recent FDA approvals for doxorubicin HCl liposome injection (Doxil®) for patients with ovarian cancer, paclitaxel protein-bound particles for injectable suspension (Abraxane™) for the treatment of breast cancer, and erlotinib (Tarceva®) therapy for patients with non–small cell lung cancer.